Clinical Trial Detail

NCT ID NCT01989676
Title A Study Of PF-05280014 [Trastuzumab-Pfizer] Or HerceptinĀ® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Trastuzumab

Paclitaxel + Trazimera

Age Groups: adult senior

Additional content available in CKB BOOST